New treatments and therapies for Crohn’s and Ulcerative Colitis are currently being explored with a whole range of research being conducted for treatment of these conditions, giving new hope for those looking for more efficient ways to manage their disease and ease their symptoms.
- Approximately 233,000 Canadians are living with Inflammatory Bowel Disease (IBD)
- 104,000, live with Ulcerative Colitis
- 129,000 live with Crohn’s Disease
Research on rodent models of human Ulcerative Colitis have shown that cannabinoids can be used to reduce inflammation at the level of involved tissues and individual cells. Among humans, cannabis has been used to treat a number of gastrointestinal disorders and symptoms that affect those with Crohn’s and Colitis such as vomiting, diarrhea, and loss of appetite.
Researchers across Canada are looking into the efficacy of this treatment, and Crohn’s and Colitis Canada strongly urges patients who are not participating in a research ethics-approved clinical trial setting not to perform fecal transplantation themselves, or to accept a fecal transplant outside of ethically approved clinical trial and to wait for scientific evidence as there is significant safety concerns and risk of serious infection. There has been some success with this treatment, but there have been documented cases where this solution made the patient’s symptoms worse.
New Drugs For Crohn’s and Colitis
There are several clinical trials and alternative research into new drugs to treat Crohn’s, colitis, and inflammatory bowel disease. Given there is no one all encompassing treatment for these conditions, and drugs currently used to treat IBD deactivate the immune system in a very nonspecific manner, it might be the best option for you to ask your healthcare provider about these new medications.
To find out more about emerging treatments for Crohn’s and Colitis visit the Share Lawyers Blog.